Nuclear magnetic resonance-based metabolomics of exhaled breath condensate: methodological aspects.

1 Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219–1263. 2 Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rhokinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 2000; 522: 177–185. 3 Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420: 629–635. 4 Abe K, Shimokawa H, Morikawa K, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004; 94: 385–393. 5 Dahal BK, Kosanovic D, Pamarthi PK, et al. Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. Eur Respir J 2010; 36: 808–818. 6 Mouchaers KT, Schalij I, de Boer MA, et al. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J 2010; 36: 800–807. 7 Oka M, Homma N, Taraseviciene-Stewart L, et al. Rho kinasemediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007; 100: 923–929. 8 Fukumoto Y, Matoba T, Ito A, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005; 91: 391–392. 9 Ishikura K, Yamada N, Ito M, et al. Beneficial acute effects of rhokinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006; 70: 174–178. 10 Abbas AE, Fortuin FD, Schiller NB, et al. A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol 2003; 41: 1021–1027. 11 Fujita H, Fukumoto Y, Saji K, et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 2010; 25: 144–149.